23andMe Public Company (NYSE:ME)
🚀 Merged with VG Acquisition Corp. on February 4, 2021. in a SPAC deal worth $3.5B, raising $900M in the process.
Founded in 2006, 23andMe is the leading consumer genetics and research company. Its test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. The company's services include ancestry, health and traits genetic insights that help people access, understand, and benefit from the human genome. 23andMe has millions of customers worldwide, with more than 80 percent of customers consented to participate in research.
Select investors GV, New Enterprise Associates, Sequoia Capital, Fidelity Investments, Casdin Capital, Illumina
Last update: April 1, 2022
Disclaimer: We can not guarantee that the information on this page is 100% correct. more